Long-term safety of ustekinumab for psoriasis

Expert Opinion on Drug Safety

Volumn 12, Issue 5, 2013, Pages 757-765

  Kumar, Neal ^a   Narang, Kirti ^a   Cressey, Brienne D ^b   Gottlieb, Alice B ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Long term safety; Psoriasis; Safety; Ustekinumab

Indexed keywords

ADALIMUMAB; CREATINE KINASE; ETANERCEPT; INFLIXIMAB; PLACEBO; TRIACYLGLYCEROL; TROPONIN; TUBERCULOSTATIC AGENT; USTEKINUMAB;

ANTIBIOTIC PROPHYLAXIS; APPENDICITIS; AREA UNDER THE CURVE; BREAST CANCER; COMMON COLD; CREATINE KINASE BLOOD LEVEL; DEMYELINATING DISEASE; DERMATOLOGY LIFE QUALITY INDEX; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; IMMUNOGENICITY; LYMPHOMA; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MYALGIA; PANCREATITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; POSTMARKETING SURVEILLANCE; PSORIASIS; REVIEW; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; PSORIASIS;

EID: 84883032847     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.808330     Document Type: Review

References (29)

1. Sterry W, Barker J, Boehncke W, et al. Biological therapies in the systemic management of psoriasis: international consensus conference. Br J Dermatol 2004;151(s69):3-17
2. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199(1):125-30
3. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296(14):1735-41
4. Liang SC, Tan X, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203(10):2271-9
5. Nograles K, Zaba L, Guttman Yassky E, et al. Th17 cytokines interleukin (IL)- 17 and IL-22 modulate distinct inflammatory and keratinocyteresponse pathways. Br J Dermatol 2008;159(5):1092-102
6. Harper EG, Guo C, Rizzo H, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009;129(9):2175-83
7. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128(5):1207-11
8. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009;129(6):1339-50
9. Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004;123(6):1037-44
10. Gottlieb AB, Cooper KD, McCormick TS, et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 2007;23(5):1081-92
11. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356(6):580-92
12. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371(9625):1665
13. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371(9625):1675-84
14. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362(2):118-28
15. Tsai T, Ho J, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 2011;63(3):154-63
16. Igarashi A, Kato T, Kato M, et al. Efficacy and safety of ustekinumab in Japanese patients with moderate to severe plaque type psoriasis: Long term results from a phase 2/3 clinical trial. J Dermatol 2011;39(3):242-52
17. Gratton D, Szapary P, Goyal K, et al. Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. Arch Dermatol 2011;147(10):1197
18. Reich K, Papp K, Griffiths C, et al. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol 2012;11(3):300-12
19. Papp K, Griffiths C, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013;168(4):844-54
20. Data on file. Janssen Biotech, 2013
21. Tsai T, Ho V, Song M, et al. The safety of ustekinumab treatment in patients with moderate to severe psoriasis and latent tuberculosis infection. Br J Dermatol 2012;167(5):1145-52
22. Young L, Czarnecki D. The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis. Australas J Dermatol 2012;53(1):57-60
23. Janssen Biotech, Inc. Highlights of prescribing information: Stelara (ustekinumab) injection, for subcutaneous use. 2013.Available from: www.stelarainfo. com/pdf/PrescribingInformation.pdf [Accessed January 10, 2013]
24. Pariser DM, Leonardi CL, Gordon K, et al. Integrated safety analysis: short-and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol 2011;67(2):245-56
25. Leonardi C, Papp K, Strober B, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol 2011;12(5):321-37
26. Menter A, Reich K, Gottlieb A, et al. Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. J Drugs Dermatol 2008;7(12):1137
27. Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol 2011;66(5):742-51
28. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-a antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011;306(21):2331-9
29. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med 2005;353(21):2262-9